PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 11, 2012, Pages 2690-2700

  Deharvengt, Sophie J ^a   Tse, Dan ^a   Sideleva, Olga ^a   McGarry, Caitlin ^a   Gunn, Jason R ^a,b   Longnecker, Daniel S ^a   Carriere, Catherine ^a   Stan, Radu V ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

Angiogenesis; Caveolae; Fenestrae; Pancreatic cancer; Transendothelial channels; Tumour microenvironment; Vesiculo vacuolar organelles

Indexed keywords

CARRIER PROTEIN; MEMBRANE PROTEIN; PLVAP PROTEIN, MOUSE; SMALL INTERFERING RNA;

ADENOCARCINOMA; ANIMAL; ARTICLE; CELL MOTION; DOWN REGULATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LENTIVIRINAE; METABOLISM; MOLECULAR GENETICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; STROMA CELL; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LENTIVIRUS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; STROMAL CELLS;

LENTIVIRUS; MURINAE; MUS;

EID: 84868096281     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01587.x     Document Type: Article

References (45)

1. Stan RV, Roberts WG, Predescu D, et al. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol Biol Cell. 1997; 8: 595-605.
2. Stan RV, Ghitescu L, Jacobson BS, et al. Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J Cell Biol. 1999; 145: 1189-98.
3. Ghitescu LD, Crine P, Jacobson BS. Antibodies specific to the plasma membrane of rat lung microvascular endothelium. Exp Cell Res. 1997; 232: 47-55.
4. Stan RV, Kubitza M, Palade GE. PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad Sci USA. 1999; 96: 13203-7.
5. Tse D, Stan RV. Morphological heterogeneity of endothelium. Semin Thromb Hemost. 2010; 36: 236-45.
6. Stan RV, Tkachenko E, Niesman IR. PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell. 2004; 15: 3615-30.
7. Stan RV. Multiple PV1 dimers reside in the same stomatal or fenestral diaphragm. Am J Physiol Heart Circ Physiol. 2004; 286: H1347-53.
8. Ioannidou S, Deinhardt K, Miotla J, et al. An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci USA. 2006; 103: 16770-5.
9. Tkachenko E, Tse D, Sideleva O, et al. Caveolae, fenestrae and transendothelial channels retain PV1 on the surface of endothelial cells. PLoS One. 2012; 7: e32655.
10. Stan RV. Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. J Cell Mol Med. 2007; 11: 621-43.
11. Madden SL, Cook BP, Nacht M, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol. 2004; 165: 601-8.
12. Carson-Walter EB, Hampton J, Shue E, et al. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumour angiogenesis. Clin Cancer Res. 2005; 11: 7643-50.
13. Shue EH, Carson-Walter EB, Liu Y, et al. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci. 2008; 9: 29.
14. Liu Y, Carson-Walter EB, Cooper A, et al. Vascular gene expression patterns are conserved in primary and metastatic brain tumours. J Neurooncol. 2010; 99: 13-24.
15. Strickland LA, Jubb AM, Hongo JA, et al. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J Pathol. 2005; 206: 466-75.
16. Niemela H, Elima K, Henttinen T, et al. Molecular identification of PAL-E, a widely used endothelial-cell marker. Blood. 2005; 106: 3405-9.
17. Keuschnigg J, Henttinen T, Auvinen K, et al. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood. 2009; 114: 478-84.
18. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992; 99: 683-90.
19. Sanders Strickland LA, Koeppen H. Comments on plasmalemmal vesicle associated protein-1 as a novel marker implicated in brain tumour angiogenesis. Clin Cancer Res. 2006; 12: 2649-50.
20. ACS American Cancer Society. Cancer facts and figures 2012. American Cancer Society; 2012. Available at http://www.cancer.org/acs/groups/content/epidemiologysurveilance/documents/document/acspc-031941.pdf.
21. Abbruzzese JL. Adjuvant therapy for surgically resected pancreatic adenocarcinoma. JAMA. 2008; 299: 1066-7.
22. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-25.
23. Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm. 2011; 68: 573-84.
24. Hallmann R, Mayer DN, Berg EL, et al. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn. 1995; 202: 325-32.
25. Deharvengt SJ, Gunn JR, Pickett SB, et al. Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther. 2009; 17: 325-33.
26. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272: 263-7.
27. Falcon BL, Pietras K, Chou J, et al. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol. 2011; 178: 2920-30.
28. Moreira LR, Schenka AA, Latuf-Filho P, et al. Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors. Tumour Biol. 2011; 32: 527-34.
29. Rao J, Otto WR. Fluorimetric DNA assay for cell growth estimation. Anal Biochem. 1992; 207: 186-92.
30. Montano R, Chung I, Garner KM, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012; 11: 427-38.
31. Montesano R, Pepper MS, Mohle-Steinlein U, et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 1990; 62: 435-45.
32. Dineen SP, Sullivan LA, Beck AW, et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumour burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer. 2008; 8: 352.
33. Okaji Y, Tsuno NH, Kitayama J, et al. A novel method for isolation of endothelial cells and macrophages from murine tumours based on Ac-LDL uptake and CD16 expression. J Immunol Methods. 2004; 295: 183-93.
34. Yanagawa J, Walser TC, Zhu LX, et al. Snail promotes CXCR2 ligand-dependent tumour progression in non-small cell lung carcinoma. Clin Cancer Res. 2009; 15: 6820-9.
35. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumour blood vessels. Am J Pathol. 2009; 175: 2159-70.
36. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6: 273-86.
37. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298-307.
38. Kalluri R, Kanasaki K. RNA interference: generic block on angiogenesis. Nature. 2008; 452: 543-5.
39. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452: 591-7.
40. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002; 94: 883-93.
41. Goetz JG, Lajoie P, Wiseman SM, et al. Caveolin-1 in tumour progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27: 715-35.
42. Chang SH, Feng D, Nagy JA, et al. Vascular permeability and pathological angiogenesis in caveolin-1-null mice. Am J Pathol. 2009; 175: 1768-76.
43. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002; 62: 5381-5.
44. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumour microvascular permeability by cavtratin blocks tumour progression in mice. Cancer Cell. 2003; 4: 31-9.
45. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331: 1565-70.